0000950170-24-098049.txt : 20240816 0000950170-24-098049.hdr.sgml : 20240816 20240816160509 ACCESSION NUMBER: 0000950170-24-098049 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240812 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240816 DATE AS OF CHANGE: 20240816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acasti Pharma Inc. CENTRAL INDEX KEY: 0001444192 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35776 FILM NUMBER: 241216674 BUSINESS ADDRESS: STREET 1: 103 CARNEGIE CENTER STREET 2: SUITE 300 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-649-9272 MAIL ADDRESS: STREET 1: 103 CARNEGIE CENTER STREET 2: SUITE 300 CITY: PRINCETON STATE: NJ ZIP: 08540 8-K 1 acst-20240812.htm 8-K 8-K
0001444192false00014441922024-08-122024-08-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2024

 

 

ACASTI PHARMA INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Quebec

001-35776

98-1359336

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

103 Carnegie Center

Suite 300

 

Princeton, New Jersey

 

08540

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 818 839-4378

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Shares, no par value per share

 

ACST

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 12, 2024, Acasti Pharma Inc. (the “Company”) entered into an employment agreement with Prashant Kohli, the Company’s Chief Executive Officer (the “Letter Agreement”). Pursuant to the Letter Agreement, Mr. Kohli is entitled to receive an annual base salary of $500,000 and an annual discretionary bonus of up to 50% of his annual base salary as determined by the Board of Directors (the “Board”). In order to earn the discretionary bonus, Mr. Kohli must remain employed with the Company throughout the year for which the bonus is paid, and must be actively employed in good standing on the date in which the bonus is paid.

 

In addition, the Letter Agreement provides that, subject to approval by the Board, Mr. Kohli may be granted from time to time an option (an “Option”) to purchase common shares of the Company (“Common Shares”) pursuant to the Company’s stock option plan (the “Plan”), with a price per share equal to the fair market value of a Common Share, as determined by the Board at the time of the grant, which will be conditioned upon (a) Mr. Kohli’s continued employment with the Company at the time of the grant, (b) entering into an option agreement with the Company (an “Option Agreement”) and (c) any other terms and conditions set forth in the Plan, the applicable Option Agreement and as may be determined by the Board in its sole discretion at the time of grant.

 

The term of the Letter Agreement commenced on August 12, 2024 and continues until terminated in accordance therewith. Either the Company or Mr. Kohli may terminate the Letter Agreement at any time, upon advanced written notice. The Letter Agreement also imposes certain confidentiality, non-competition and non-solicitation obligations on Mr. Kohli during the term of the Letter Agreement and for a specified time thereafter. The Letter Agreement provides for standard Company benefits, such as paid vacation and participation in the Company’s employee benefit plans and programs.

 

In the event that Mr. Kohli’s employment is terminated by the Company without Cause (as defined in the Letter Agreement), including after a change of control, and subject to his delivery to the Company of a general release of claims in a form acceptable to the Company, the Company will pay Mr. Kohli a continuation of his base salary then in effect for twelve (12) months after termination.

 

In connection with executing the Letter Agreement, Mr. Kohli also entered into the Company’s standard form of Confidentiality of Information and Ownership of Proprietary Property Agreement, which, among other things, (a) acknowledges the Company’s ownership rights in any proprietary property, (b) assigns any such ownership rights to the Company and (c) prohibits Mr. Kohli from disclosing certain confidential or proprietary information of the Company.

The foregoing description of the Letter Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Letter Agreement, which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

 

Description

10.1

 

Letter Agreement by and between Prashant Kohli and the Company, dated August 12, 2024.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ACASTI PHARMA INC.

 

 

 

 

Date:

August 16, 2024

By:

/s/ Robert J. DelAversano

 

 

 

Robert J. DelAversano
Vice President, Finance

 

 EX-10.1 2 acst-ex10_1.htm EX-10.1 EX-10.1

Exhibit 10.1

August 12, 2024

 

PRIVATE AND CONFIDENTIAL

 

Prashant Kohli

31 Northrup Court,

Newtown, PA 18940

p.kohli@acasti.com

 

Dear Prashant:

 

This Letter Agreement (“Letter Agreement”) sets forth the terms and conditions of your employment with Acasti Pharma Inc. (the "Company”), and supersedes in its entirety the Welcome Letter between you and Acasti, dated August 25, 2021.

 

Title: Chief Executive Officer

 

Reporting to: The Board of Directors

 

Base Salary: Annualized base salary of $500,000 less applicable deductions and withholdings.

 

Annual Discretionary

Bonus: You will be eligible to earn an annual discretionary bonus of up to 50% of your base salary as determined by the Company in its sole discretion. The discretionary bonus, if any, for a given year will be paid no later than May 15th in the year following the completion of the relevant fiscal year. In order to earn the discretionary bonus, you must remain employed with the Company throughout the year for which the bonus is paid, and must be actively employed in good standing on the date in which the bonus is paid.

 

Stock Option: Subject to approval by the board of directors of the Company, you may be granted from time to time an option to purchase common shares in the capital of the Company (the “Option”) pursuant to the Company’s equity incentive plan (the “Plan”), with a price per share equal to the fair market value of a common share, as determined by the board of directors at the time of the grant. Any grant of the Option to you shall be conditional upon: (a) your continued employment with the Company at the time of the grant; (b) you entering into an option agreement with the Company (the “Option Agreement”); and (c) any other terms and conditions set forth in the

1

 

Plan, your Option Agreement and as may be determined by the board of directors in its sole discretion at the time of grant.

 

Benefits: Subject to the terms and conditions of the applicable benefit plans and policies, you will be eligible to participate in such group benefit plans as the Company may make available for executives from time to time in its sole discretion.

 

Vacation: Vacation entitlement, including treatment of unused vacation time, will be in accordance with the Company’s vacation policy for executives as in effect from time to time.

 

Severance: If you are terminated by the Company without Cause (as defined below) including after change of control, provided that you execute and deliver to Company within sixty (60) days of your termination a general release of claims in a form acceptable to the Company, and do not revoke the same, the Company shall pay you a continuation of your base salary then in effect for twelve (12) months if your employment is terminated without Cause.

 

For the purposes of this Letter Agreement, “Cause” shall mean your (a) material failure to comply with any material Company policy to the satisfaction of the Board which is not cured within twenty (20) calendar days of receipt by you of notice of such failure (if such action is curable); (b) willful failure to carry out or comply with any material, lawful, and reasonable written directive from the Board, which is not cured within twenty (20) calendar days of receipt by you of notice of such failure (if such action is curable); (c) commission of any act or omission that results in, or that may reasonably be expected to result in, a conviction, plea of no contest or imposition of unadjudicated probation for any felony or any crime involving moral turpitude; (d) commission of any act or omission that results in your incarceration in a federal, state, or local jail or prison; (e) unlawful use (including being under the influence) or possession of illegal drugs on the Company’s premises or while performing your duties and responsibilities to the Company; (f) commission of any act of dishonestly, illegal conduct, fraud, embezzlement, misappropriation, material misconduct, or breach of fiduciary duty either (i) against the Company or any of its parent, subsidiary, or affiliate entities (collectively, “Affiliates”) (or any predecessor thereto or successor thereof) or (y) which is or which is reasonably expected to be materially injurious to the Company or its

2

 

Affiliates; or (g) material or willful breach of the Confidentiality Agreement (defined below) which is not cured within ten (10) calendar days after receipt by you of written notice of such breach (if such breach is curable).

 

Non-Competition You undertake to not work, for the duration of this Letter Agreement and for a period of twelve (12) months following the end of this contract for any reason whatsoever, directly or indirectly, personally or through an intermediary, alone or through a company or corporation, jointly with any other person, company, or corporation, as a principal, agent, shareholder, or in any other capacity, within the territories of any country in which the Company does business or in any jurisdiction in which the Company holds patents, for a company of a similar nature as that operated by the Company, which presently is a late-stage biopharmaceutical company pursuing the 505(b)2 regulatory pathway with drug candidates addressing rare and orphan diseases, specifically aneurysmal subarachnoid hemorrhage, ataxia-telangiectasia, postherpetic neuralgia and other undisclosed indications associated with GTX-201, and to not use the Company's know-how for any purpose whatsoever (a “Competitive Business”). You understand that the Company’s business is subject to change over time and the definition of Competitive Business shall be subject to corresponding changes as mutually agreed between parties. However, nothing precludes you from being or becoming a shareholder in a public company with a Competitive Business, i.e., a company whose shares are publicly traded, competing with the Company, provided you hold no more than 5% of the shares issued and outstanding comprising said public company’s capital stock.

 

Non-Solicitation For the duration of this Letter Agreement and for a period of twelve (12) months following the end of this Letter Agreement for any reason whatsoever, you undertake to not directly or indirectly solicit or convince any other person, including an employee of the Company, to terminate his/her business or employment relations with the Company, or to commit any act likely to harm or rival the Company.

 

Simultaneous to signing this Letter Agreement, you agree to execute the Company’s standard form Confidentiality of Information and Ownership of Proprietary Property Agreement (“Confidentiality Agreement”). You further agree that your continued employment constitutes good and sufficient consideration for the enforcement of the provisions set forth herein and in the Confidentiality Agreement. You agree that the restrictive covenants herein and in the

3

 

Confidentiality Agreement are reasonable for the position you hold and the benefits and amenities provided for in your Letter Agreement. If a court of competent jurisdiction determines that any provision of this Letter Agreement (or portion thereof) is invalid or unenforceable, then the invalidity or unenforceability of that provision (or portion thereof) shall not affect the validity or enforceability of any other provision of this Letter Agreement, and all other provisions shall remain in full force and effect. It is the intention of the parties that any such invalid or unenforceable provision be reformed and enforced to the fullest extent permitted by law. Further, you acknowledge that it may be impossible to assess the damages caused by your violation of the restrictive covenants herein and in the Confidentiality Agreement and further agree that any threatened or actual violation or breach of those provision will constitute immediate and irreparable injury to the Company. You therefore agree that any such breach of this Agreement is a material breach of this Agreement and/or the Confidentiality Agreement, and, in addition to any and all other damages and remedies available to the Company upon your breach of this Agreement and/or the Confidentiality Agreement, the Company shall be entitled to an injunction to prevent you from violating or breaching this Agreement and/or the Confidentiality Agreement.

 

Your employment with the Company is at-will, which means that you have the right to terminate your employment with the Company at any time, for any reason. Similarly, the Company has the right to terminate the employment relationship at any time, for any reason.

 

If your employment is terminated without Cause, the Company shall provide you with up to 60 days’ advance written notice. The Company may, at any time during such notice period, relieve you from all or any of your duties for all or part of the remainder of the notice period and/or terminate you at any time without impact to salary for the remainder of the notice period.

 

If you resign your employment, you agree to provide the Company with 60 days’ advance written notice. The Company may, at any time during such notice period, relieve you from all or any of your duties for all or part of the remainder of the notice period and/or consider your resignation effective as of any date within the notice period. In the event that the Company accepts your resignation as of any date within the notice period, as of such date, you shall not be paid your base salary or other benefits in accordance with this Letter Agreement, and you shall not be entitled to any severance benefits.

 

Any contrary representations, which may have been made to you, are superseded by this Letter Agreement. Any modifications to this “at-will” term of your employment must be in writing and signed by you and the Board.

 

This Letter Agreement shall be governed by the laws of the Commonwealth of Pennsylvania, without regard to conflicts of law.

 

 

4

 

We look forward to your continued commitment to the Company and the goal of advancing science in support of better patient outcomes.

 

Sincerely,

 

Vimal Kavuru

 

5

 

 

I have read, understand and accept these terms and conditions of employment. I further understand that while my salary, benefits, job title and job duties may change from time to time without a written modification of this agreement, the at-will term of my employment is a term of employment which cannot be altered or modified except in writing, signed by me and the Company’s Board of Directors. By accepting this offer, I confirm that I am able to accept this job and carry out the work involved without breaching any legal restrictions on my activities, such as restrictions imposed by a current or former employer.

 

 

Signature /s/ Prashant Kohli Date August 12, 2024

 

 

ACASTI PHARMA Inc.

 

By: /s/ Robert J. DelAversano

Name: Robert J. DelAversano

Title: Vice President, Finance

Date: August 12, 2024

 

 

 

6

 EX-101.SCH 3 acst-20240812.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Document And Entity Information
Aug. 12, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 12, 2024
Entity Registrant Name ACASTI PHARMA INC.
Entity Central Index Key 0001444192
Entity Emerging Growth Company false
Entity File Number 001-35776
Entity Incorporation, State or Country Code A8
Entity Tax Identification Number 98-1359336
Entity Address, Address Line One 103 Carnegie Center
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code 818
Local Phone Number 839-4378
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value per share
Trading Symbol ACST
Security Exchange Name NASDAQ
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *2 $%D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "D@!!9]:G1 >X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)^WJ(J&;B^))07!!\1:2V=U@TX1DI-VW-XV[740?0,@E,W^^ M^0;2Z2"TC_@@M(? M:H_08T8 ].APH05,WP.0\ M,1RGOH,+8(811I>^"V@68JG^B2T=8*?DE.R2&L>Q'E621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M *2 $%E!]U3$: 0 #,1 8 >&PO=V]R:W-H965T&UL MC9AO<^(V$,:_BL:=Z;0S2?R7 "DPXY"D1^^2HS'MS;33%\(6H#E;J/-#_9DE-,UBYC^(Y\K.+-KE81G3!1<"J+8:FR%[LVMUS,! MU1U_#Q M\4']H1H\#&9)"S:5Z3>>Z,W8&E@D82M:IOI9;C^Q_8 JP%BF1?5)MKM[@\ B M<5EHF>V#@2#C8O=-7_>). KP!R<"O'V 5W'O'E11WE%-)R,EMT29NT'-'%1# MK:(!C@LS*Y%6<)5#G)[86^UX+WB[ M$_1."(;E^HJXW@7Q'"]X'VX#6PWHU8!>I>>?T)O*%Z;(W^&RT JF\)\VHIU" MT*Y@ZOJFR&G,QA84;L'4"[,F/_[@7CN_('Q^S>=CZDT"%V\Y:X/#PP>7GQ&( MH(8(4)40")**XB&EZS8*/'Y%TX(A'+V:HW=>,N9,<6D**B%0EJUYP97J,NJJ MH^L:[1H5W-?V,UMS4TG ^$2S5C!<)YR&T6)&YI_"Y\>0S)ZF5PAVO!P)<=QW" (W*&'8 UJK,$Y6/<94VLNUN17B-<;,I59 M3D4K'*[756;#FFMX#M<#3QEY*K,E4VTLN ;DZ=+O]?O7"(_K-"[JG$,T$[%4 MN525=UZ02$/M$ZD@8R7,+$RP3%I+KD,]'&"01U;OG@.YH*]DED"I\16/*U(D MB1V2P\&EZ_>&OH^FL?%Z%[7J V&8)Q<7A@'R!^\A7T9X[7-)U?#*E2L"Z M9]4"^SC.]ZB-[;NX<:.HBZUL1<4EHY)#N?B.@P$V+<'%/?TCX-2<02TNY+:] MK>-R<\5%S/3'+<%[N*9/N+B]?X2K5\I[@U+[B&O89PYWYD"YR_QIOJ%BSDWOO#J&G,+H+?V]CLH]>@?56O)0:WK&KPPVC4&WF!KB^DE(?3LR+=OT_ MR>0_4$L#!!0 ( *2 $%F?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND M,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0& M@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&- M!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+ MY2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'D ML\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y M+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^ M7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM! M)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z M!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C M$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7 M,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( *2 $%F7BKL

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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports acst-20240812.htm acst-20240812.xsd http://xbrl.sec.gov/dei/2024 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "acst-20240812.htm": { "nsprefix": "acst", "nsuri": "http://www.acastipharma.com/20240812", "dts": { "inline": { "local": [ "acst-20240812.htm" ] }, "schema": { "local": [ "acst-20240812.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_6b975dc0-069b-4a89-82d6-7aed94929edb", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "acst-20240812.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_6b975dc0-069b-4a89-82d6-7aed94929edb", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "acst-20240812.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.acastipharma.com/20240812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-24-098049-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-098049-xbrl.zip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acst-20240812_htm.xml IDEA: XBRL DOCUMENT 0001444192 2024-08-12 2024-08-12 0001444192 false 8-K 2024-08-12 ACASTI PHARMA INC. A8 001-35776 98-1359336 103 Carnegie Center Suite 300 Princeton NJ 08540 818 839-4378 false false false false Common Shares, no par value per share ACST NASDAQ false